SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase I/II dose escalation and expansion trial. The primary objective
of dose escalation phase I study is to evaluate the safety and feasibility of SHR1701 in
patients with relapsed or refractory classical Hodgkin Lymphoma. The primary objective of
open-label, randomized, phase II study is to assess the antitumor effect of SHR1701 alone or
in combination with SHR2554 in patients with relapsed or refractory classical Hodgkin
Lymphoma.